Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pozelimab in PNH
NCT03946748Phase 2Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- May 2019
- Primary completion
- Jun 2021
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 5
01
Overview
A Phase 2 trial of pozelimab in paroxysmal nocturnal hemoglobinuria (PNH), sponsored by Regeneron Pharmaceuticals. Started May 2019; status: completed.
02
Drugs
pozelimab
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on NCT03946748.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03946748.